MX2019002579A - Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. - Google Patents

Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.

Info

Publication number
MX2019002579A
MX2019002579A MX2019002579A MX2019002579A MX2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A MX 2019002579 A MX2019002579 A MX 2019002579A
Authority
MX
Mexico
Prior art keywords
nafld
nash
ald
gamma
compositions
Prior art date
Application number
MX2019002579A
Other languages
English (en)
Inventor
Rathmacher John
Abumrad Naji
Flynn Charles
Original Assignee
Metabolic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Tech Inc filed Critical Metabolic Tech Inc
Publication of MX2019002579A publication Critical patent/MX2019002579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se describen métodos y composiciones para el uso en tratar, evitar o mejorar enfermedades relacionadas al hígado en un animal, que incluye pero no limitado a enfermedad del hígado graso no alcohólico (NAFLD), enfermedad del hígado alcohólico (ALD) o esteatohepatitis no alcohólica (NASH). Los compuestos de la presente invención son depuradores de gamma-cetoaldehído.
MX2019002579A 2016-09-06 2017-09-06 Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado. MX2019002579A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US201662410133P 2016-10-19 2016-10-19
PCT/US2017/050317 WO2018048932A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Publications (1)

Publication Number Publication Date
MX2019002579A true MX2019002579A (es) 2020-02-05

Family

ID=61562136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002579A MX2019002579A (es) 2016-09-06 2017-09-06 Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.

Country Status (8)

Country Link
US (2) US20180153827A1 (es)
EP (1) EP3510014A4 (es)
JP (2) JP7189127B2 (es)
CN (1) CN110177771B (es)
AU (1) AU2017324935B2 (es)
CA (1) CA3035897A1 (es)
MX (1) MX2019002579A (es)
WO (1) WO2018048932A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517721A (ja) 2017-04-27 2020-06-18 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ γ−ケトアルデヒドスカベンジャーによるアテローム性動脈硬化症の治療方法
MX2020002441A (es) * 2017-09-05 2020-09-03 Mti Biotech Inc Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762030B2 (en) * 1998-10-22 2003-06-19 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
CA2369560C (en) * 1999-04-27 2011-02-01 Makoto Nakamuta Agent for prophylaxis and treatment of liver disease
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
KR101209319B1 (ko) * 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CA2844150C (en) 2011-07-12 2019-09-03 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
WO2013168013A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna
JP2017537149A (ja) * 2014-11-11 2017-12-14 ヴァンダービルト ユニバーシティー 急性腎傷害を制限するための方法
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
MX2020002441A (es) * 2017-09-05 2020-09-03 Mti Biotech Inc Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.

Also Published As

Publication number Publication date
AU2017324935A1 (en) 2019-03-28
US20230181494A1 (en) 2023-06-15
AU2017324935B2 (en) 2021-10-21
EP3510014A4 (en) 2020-05-20
CN110177771B (zh) 2022-12-13
JP7189127B2 (ja) 2022-12-13
CA3035897A1 (en) 2018-03-15
US20180153827A1 (en) 2018-06-07
EP3510014A1 (en) 2019-07-17
CN110177771A (zh) 2019-08-27
JP2023022236A (ja) 2023-02-14
WO2018048932A1 (en) 2018-03-15
BR112019004404A2 (pt) 2019-05-28
JP2019526598A (ja) 2019-09-19

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2017009532A (es) Uso de acidos grasos de cadena corta en prevencion de cancer.
PH12020550833A1 (en) Rnai constructs for inhibiting pnpla3 expression
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
MX2021011949A (es) Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2022007816A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
IL284345A (en) Preparations and methods for the treatment of non-alcoholic fatty liver diseases
MX2021006784A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos.
PH12017550090B1 (en) Composition for improving or preventing nonalcoholic fatty liver
MX2021003156A (es) Tratamiento para la enfermedad del higado graso no alcoholico.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии
EP3366296A4 (en) METHODS OF USING REGULATORS FOR INCREASING THE EXPRESSION OR ACTIVATION OF P53 AND / OR REDUCTION REGULATORS OR INHIBITORS OF P63-ALPHA EXPRESSION FOR THE TREATMENT OF NAFLD (NON-ALCOHOLIC HEPATIC STÉATOSE) AND / OR NASH (NON-ALCOHOLIC STÉATOHÉPATITE)